Lupin Ltd
About
Lupin is a global pharmaceutical company that was established in 1968 by Dr. Desh Bandhu Gupta. Currently headquartered in Mumbai, the company marks its presence across the US, Asia-Pacific, Latin America, the Middle East, Europe, and Africa. With the support of 15 manufacturing facilities and 7 research centres in India, Brazil, Mexico, and the US, Lupin is able to distribute its portfolio of more than 1200 products to more than 100 markets across the world. Its products include generics, complex generics, branded generics, biosimilars, active pharmaceutical ingredients (APIs), and specialty medicines designed for key therapeutic areas of respiration, cardiology, diabetes, gastroenterology, gynaecology, and more. Lupin Diagnostics, Atharv Ability, and Lupin Digital Health assist the company in its commitment to improving public health.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 20599 23.8% | 16639 -1.0% | 16814 6.5% | 15785 -1.2% | 15984 4.5% | 15300 -3.1% | 15788 -11.4% | 17820 19.7% | 14892 13.2% | 13155 13.4% | 11603 17.7% | 9861 33.0% | 7414 25.0% | 5932 21.2% | 4895 24.3% | 3939 - |
| Net Operating Income (INR Cr) | 20011 20.25% | 16642 1.44% | 16405 8.19% | 15163 -1.38% | 15375 4.84% | 14665 -7.17% | 15797 -9.04% | 17367 21.83% | 14256 11.63% | 12770 13.14% | 11287 17.06% | 9641 36.12% | 7083 21.72% | 5819 21.90% | 4774 26.42% | 3776 40.57% |
| Profit (INR Cr) | 1914 345.2% | 430 - | -1528 - | 1217 - | -269 - | 607 141.4% | 251 -90.2% | 2557 13.1% | 2261 -5.9% | 2403 30.9% | 1836 39.7% | 1314 51.5% | 868 0.6% | 863 26.5% | 682 35.9% | 502 - |
| Assets (INR Cr) | 18016 1.3% | 17789 4.0% | 17099 -13.6% | 19799 -1.4% | 20071 -14.2% | 23386 8.1% | 21643 -3.4% | 22410 17.7% | 19041 97.5% | 9641 23.1% | 7831 18.8% | 6591 12.1% | 5877 28.1% | 4588 22.9% | 3733 40.2% | 2662 - |
| Net Worth (INR Cr) | 14290 14.7% | 12465 2.6% | 12153 -12.0% | 13803 10.1% | 12537 -8.8% | 13742 1.2% | 13577 0.6% | 13498 20.9% | 11163 25.8% | 8874 28.0% | 6932 33.2% | 5204 29.7% | 4013 22.3% | 3281 27.8% | 2568 80.2% | 1425 11.3% |
| Employee Cost (INR Cr) | 3495 13.2% | 3087 3.3% | 2989 5.8% | 2826 -5.4% | 2987 7.8% | 2770 -3.3% | 2865 0.5% | 2850 33.1% | 2142 22.6% | 1747 19.3% | 1465 15.6% | 1267 30.6% | 970 26.3% | 768 30.7% | 587 23.8% | 474 - |
| Interest Cost (INR Cr) | 312 | 274 | 143 | 141 | 363 | 302 | 204 | 153 | 59 | 10 | 27 | 41 | 35 | 34 | 38 | 50 |
| Cash & Bank Balance (INR Cr) | 1203 | 1293 | 1098 | 1742 | 2454 | 987 | 1408 | 698 | 822 | 481 | 798 | 435 | 402 | 420 | 202 | 78 |
| Total Debt (INR Cr) | 2922 | 4542 | 4158 | 5129 | 6305 | 8496 | 7143 | 7966 | 7178 | 537 | 654 | 1164 | 1639 | 1162 | 1140 | 1223 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 9.3% | 2.6% | - | 7.7% | - | 4.0% | 1.6% | 14.4% | 15.2% | 18.3% | 15.8% | 13.3% | 11.7% | 14.5% | 13.9% | 12.7% |
| Profit As % Of Assets | 10.6% | 2.4% | - | 6.1% | - | 2.6% | 1.2% | 11.4% | 11.9% | 24.9% | 23.5% | 19.9% | 14.8% | 18.8% | 18.3% | 18.8% |
| Profit As % Of Networth | 13.4% | 3.5% | - | 8.8% | - | 4.4% | 1.9% | 19.0% | 20.3% | 27.1% | 26.5% | 25.3% | 21.6% | 26.3% | 26.5% | 35.2% |
| Interest Cost to EBITDA % | 8.2% | 15.9% | 65.3% | 5.5% | 22.7% | 13.6% | 12.1% | 3.4% | 1.6% | 0.3% | 0.9% | 1.8% | 2.5% | 2.9% | 4.3% | 7.7% |
| Debt to Equity Ratio | 0.20 | 0.36 | 0.34 | 0.37 | 0.50 | 0.62 | 0.53 | 0.59 | 0.64 | 0.06 | 0.09 | 0.22 | 0.41 | 0.35 | 0.44 | 0.86 |
| RONW | 14.5% | 3.6% | - | 9.3% | - | 5.4% | 2.1% | 20.8% | 22.7% | 30.9% | 30.7% | 28.7% | 23.9% | 29.7% | 34.7% | 37.2% |
| ROCE | 15.3% | 5.7% | -6.7% | 9.1% | 8.7% | 9.4% | 9.8% | 17.9% | 23.7% | 39.4% | 39.8% | 31.5% | 23.5% | 24.7% | 27.3% | 25.5% |